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Abstract
It is now well established that the clade of simian immunodeficiency viruses (SIVs) infecting west central African chimpanzees (Pan
troglodytes troglodytes) and western gorillas (Gorilla gorilla gorilla) comprises the progenitors of human immunodeficiency virus type 1 (HIV-1).
In this study, we have greatly expanded our previous molecular epidemiological survey of SIVcpz in wild chimpanzees in Cameroon. The new
results confirm a wide but uneven distribution of SIVcpzPtt in P. t. troglodytes throughout southern Cameroon and indicate the absence of SIVcpz
infection in Pan troglodytes vellerosus. Analyzing 725 fecal samples from 15 field sites, we obtained partial nucleotide sequences from 16 new
SIVcpzPtt strains and determined full-length sequences for two of these. Phylogenetic analyses of these new viruses confirmed the previously
reported phylogeographic clustering of SIVcpzPtt lineages, with viruses related to the ancestors of HIV-1 groups M and N circulating exclusively
in southeastern and south central P. t. troglodytes communities, respectively. Importantly, the SIVcpzPtt strains from the southeastern corner of
Cameroon represent a relatively isolated clade indicating a defined geographic origin of the chimpanzee precursor of HIV-1 group M. Since
contacts between humans and apes continue, the possibility of ongoing transmissions of SIV from chimpanzees (or gorillas) to humans has to be
considered. In this context, our finding of distinct SIVcpzPtt envelope V3 sequence clades suggests that these peptides may be useful for the
serological differentiation of SIVcpzPtt and HIV-1 infections, and thus the diagnosis of new cross-species transmissions if they occurred.
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Numerous African primates are infected with simian
immunodeficiency viruses (SIVs), and it is now well established
that SIVs infecting chimpanzees (Pan troglodytes troglodytes)
and western gorillas (Gorilla gorilla gorilla) in west central⁎ Corresponding author. Fax: +33 0467416146.
E-mail address: martine.peeters@mpl.ird.fr (M. Peeters).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.06.018Africa are the progenitors of human immunodeficiency virus
type 1 (HIV-1) (Bibollet-Ruche et al., 2004a; Gao et al., 1999;
Keele et al., 2006; Van de Woude and Apetrei, 2006; Van
Heuverswyn et al., 2006). The three groups of HIV-1 (groups
M, N and O) are the result of three independent cross-species
transmission events (Hahn et al., 2000; Sharp et al., 2005).
Whereas infections with groups N and O remain mainly
confined to Cameroon and surrounding countries, HIV-1 group
M has spread worldwide and infected more than 60 million
156 F. Van Heuverswyn et al. / Virology 368 (2007) 155–171individuals (Ayouba et al., 2001; Hemelaar et al., 2006;
McCutchan, 2006; Peeters et al., 1997; Vergne et al., 2003;
Yamaguchi et al., 2006).
Chimpanzees (Pan troglodytes) are classified into four
subspecies but only the two subspecies from central Africa, P. t.
troglodytes and Pan troglodytes schweinfurthii are infected by
SIVcpz. Moreover, their viruses form divergent subspecies-
specific phylogenetic lineages, SIVcpzPtt and SIVcpzPts,
respectively (Groves, 2001; Sharp et al., 2005). All HIV-1
strains fall within the SIVcpzPtt lineage from west central
Africa and no human counterpart has yet been identified for
SIVcpzPts in chimpanzees from east central Africa (Santiago et
al., 2003a,b; Sharp et al., 2005; Worobey et al., 2004). Using
non-invasive strategies to detect antibodies and viral RNA in
ape fecal samples, we recently traced the natural reservoirs of
HIV-1 groups M and N to distinct chimpanzee populations in
southern Cameroon (Keele et al., 2006). In these communities,
prevalence rates ranged from 0% to 35% and the new
SIVcpzPtt viruses exhibited a significant phylogeographic
clustering, suggesting that major rivers or long distances were
responsible for the uneven distribution of SIVcpz strains.
Although, Cameroon is also home to the Pan troglodytes
vellerosus chimpanzee subspecies, which inhabits the forests
north of the Sanaga River, the boundary with the range of P. t.
troglodytes, no case of SIVcpz infection has thus far been
identified in this subspecies, but only a few have been sampled
(Keele et al., 2006; Nerrienet et al., 2005).
Extension of our survey in Cameroon to a second great ape
species, western gorillas (Gorilla gorilla), showed that these
apes are also endemically infected with a simian immunode-Fig. 1. Location of wild chimpanzee study sites in southern Cameroon. Circles ind
indicate field sites that were also studied previously (Keele et al., 2006). WE, MTand
WE are located in the range of P.t.vellerosus, while all other sites are located in theficiency virus, designated SIVgor (Van Heuverswyn et al.,
2006). Surprisingly, the phylogenetic relationships among
HIV-1, SIVcpz and SIVgor indicate that the gorilla viruses form
a monophyletic lineage within the SIVcpzPtt radiation, which is
much more closely related to HIV-1 group O than to any other
SIV. Although not yet detected in chimpanzees, the SIVgor
virus seemed to have a P. t. troglodytes origin, and it remains to
be determined whether chimpanzees transmitted HIV-1 group
O-like viruses to gorillas and humans independently, or first to
gorillas which then transmitted the virus to humans.
In order to confirm and extend our previous findings and to
study in more detail the genetic diversity of SIVcpz strains in
wild chimpanzee populations, we conducted a comprehensive
follow-up study to obtain more SIVcpzPtt isolates from the
same as well as from different geographic regions in Cameroon.
We also characterized two new full-length genomes and
analyzed V3 envelope sequences from additional SIVcpzPtt
strains. The latter provides new V3 peptides as potential
diagnostic tools to discriminate between SIVcpzPtt and HIV-1
infections.
Results
SIV infection of wild chimpanzees in Southern Cameroon
Fecal samples (n=725) were collected from wild-living
(non-habituated) apes at 15 forest sites, primarily located in the
southern part of Cameroon (Fig. 1). Collection sites, numbers of
collected samples, species and subspecies determinations, and
test results of SIVcpz antibody detection are summarized inicate sampling sites from the current study (n=15). Circles with grey shading
DG are sites included only in the last study (Keele et al., 2006). MF, TK, MP and
range of P.t. troglodytes.
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origin based on mtDNA analysis, with 323 from P. t.
troglodytes, collected south of the Sanaga River and 55 from
P. t. vellerosus, all collected north of the river. The remaining
specimens were either from gorillas (G. gorilla, n=213) and
have been described in our previous study (Van Heuverswyn et
al., 2006), or from other primate species (n=75) such as
baboons, agile monkeys or different Cercopithecus species. For
59 samples, the DNA was degraded and the exact species of
origin could not be determined. With the exception of BB
(where only gorilla samples were collected), chimpanzee
samples were obtained from all other sites.
All 378 chimpanzee samples were tested for the presence of
SIVcpz antibodies with the INNO-LIA HIV I/II Score
Confirmation Assay. We identified a total of 40 new SIVcpz
antibody-positive samples, collected at 5 of the 11 sites located
within the range of P. t. troglodytes apes (Table 1). These 40
specimens were also subjected to the enhanced chemilumines-
cent Western blot analysis and a similar reactivity profile was
observed (Figs. 2a and b). All samples reacted strongly with the
HIV-1 p24 core antigen, and some also did with p17. Samples
from the LB and MB collection sites in the south east also
exhibited strong cross-reactivity with HIV-1 envelope antigens;
gp41 on INNO-LIA strips and gp41, gp120, gp160 on Western
blot strips. The env cross-reactivity was weaker or absent for
samples collected in the south central region (DP, SL, and BM).
As observed previously, all Western blot profiles of chimpanzee
samples from the southeastern corner of Cameroon were
indistinguishable from the HIV-1-positive human plasma control.
In our previous study, samples were collected at 10 forest
sites (WE, MT, DG, CP, DP, BQ, EK, BB, MB, and LB) and in 5
of them (MT, DP, EK, MB, and LB) SIVcpzPtt infection was
observed with prevalence rates ranging from 4% to 35% (Keele
et al., 2006). For this survey, we obtained new chimpanzeeTable 1
SIV infection in wild chimpanzee populations from different field sites in Southern
Collection
sites a
Fecal samples
collected
Chimpanzee
samples b
P. t.
troglodytes b
P. t.
vellerosus b
TK 25 1 0 1
MF 45 39 0 39
CP 107 42 42 0
MP 44 15 0 15
MG 25 24 24 0
KG 55 15 15 0
DP 70 35 35 0
BQ 35 10 10 0
SL 45 44 44 0
EK 43 27 27 0
BM 41 38 38 0
LB 70 18 18 0
MB 81 62 62 0
NK 34 8 8 0
BB 5 0 0 0
Total 725 378 323 55
a Location of sites is shown in Fig. 1.
b As determined by mitochondrial DNA analysis of fecal DNA (see Materials an
c As determined by microsatellite analysis (Table 2).samples from 6 of these 10 sites (CP, BQ, EK, DP, LB, and
MB). In addition, we extended the sampling area to 5 new sites
(MG, KG, SL, BM and NK) in the P. t. troglodytes range and 3
new sites (TK, MF, and MP) in the P. t. vellerosus range. Like
the previously reported 23 P. t. vellerosus samples (Keele et al.,
2006), none of the additional 55 samples collected north of the
Sanaga River exhibited SIVcpz antibody reactivity, suggesting
that this subspecies is not infected with SIVcpz.
We estimated the number of individuals that were sampled
by taking into consideration the extent of sample degradation
(0.169) and oversampling (on average, each chimpanzee was
sampled 1.716 times) (Keele et al., 2006). From this, we
calculated the prevalence of SIVcpz infection at the DP, SL,
BM, LB, and MB sites. As observed before (Keele et al., 2006),
the highest prevalence rates were seen in the southeast, 33.3%
for MB and 34.5% for LB. In addition, moderate prevalence
rates were observed at the other sites, 11.7% for DP, 5.4% for
BM, and 4.7% for SL. In contrast to our previous study, no
infected chimpanzees were found in EK, although we did
identify infected chimpanzees at a new location, BM, within the
Dja Reserve just below the Dja River and approximately 35 km
west of EK. Furthermore, we identified positive samples at SL,
located at the northern periphery of the Dja Reserve, just north
of the Dja River, approximately 40 km west of DP. No evidence
for SIVcpz infection was found in NK, similar to what was
previously observed for BB, with both sites located west of the
Boumba River. Finally, no positive samples were identified at
KG and MG which were located in close proximity of DG and
MT, respectively (Fig. 1), two sites where SIVcpz prevalence
was low or absent in the previous study.
Microsatellite analyses revealed that the 40 immunoblot
reactive samples represented 17 different P. t. troglodytes apes
(Table 2). With the exception of 7 samples from MB, which
were all derived from a chimpanzee (ID25) that had an identicalCameroon
Gorilla
samples b
Other
species b
Degraded
samples b
SIVcpz
antibody-positive
samples
Number of
SIVcpz-infected
chimpanzees c
21 1 2 0 0
0 1 5 0 0
51 10 4 0 0
0 29 0 0 0
0 1 0 0 0
15 1 24 0 0
16 7 12 10 2
25 0 0 0 0
0 0 1 5 1
6 9 1 0 0
1 2 0 2 1
48 2 2 3 3
2 10 7 20 10
25 1 0 0 0
3 1 1 0 0
213 75 59 40 17
d methods).
Fig. 2. Detection of HIV-1 cross-reactive antibodies in chimpanzee fecal samples. Fecal samples from wild-living chimpanzees were tested by the INNO-LIA HIV I/II
Score Confirmation test (a) and ECLWestern blot analysis using HIV-1 antigen containing strips (b). Samples are numbered with letters indicating their collection site
as shown in Fig. 1. Samples from the same individual (ID) are grouped, individuals are numbered taking into account the previous survey (Keele et al., 2006) where 16
SIVcpzPtt positive individuals were identified. Molecular weights of HIV-1 proteins are indicated. The banding pattern of plasma from an HIV-1 infected patient and
an uninfected human control are shown.
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(Table 2), all other positive samples were derived from new
individuals. For two antibody-positive samples, DP934 and
DP946, individual assignment was not possible, because they
represented a mixture of fecal material from individuals 14 and
15 from the same collection site.
Genetic diversity of SIVcpzPtt isolates from wild chimpanzee
populations in partial pol and env regions
RNAwas extracted and subjected to RT–PCR amplification
using consensus env (gp41 and a fragment spanning the V2–V5
region) and pol primers. SIVcpz sequences were amplified for
one or more genomic regions from 16 chimpanzees (Table 2),
while despite strong antibody reactivity, one sample (MB773)
was repeatedly virion RNA negative. SIVcpz sequences were
obtained from all sites where antibody-positive chimpanzees
were identified.
To compare the evolutionary relationships of the 16 new
SIVcpzPtt viruses to each other and to previously characterized
SIVcpz, SIVgor and HIV-1 strains, phylogenies were con-
structed using partial Pol (296 aa) and Gp41 (126 aa) sequences(Figs. 3a and b). The relative positions of some strains, or
clades, differed between the two trees, providing further
evidence of recombination during the divergence of the
SIVcpzPtt lineages (Sharp et al., 2005). However, in both
trees, all SIVcpzPtt strains from MB and LB, including the 12
new strains, fell into a well-supported clade which included
HIV-1 group M. In contrast, two new strains from DP clustered
with strains obtained from captive chimpanzees in Cameroon
(CAM3 and CAM5), rather than grouping closely with the two
previously obtained strains from that same location. CAM3 is
thought to have been caught south of the Dja River (Nerrienet et
al., 2005), whereas the DP site lies north of the Dja River (Fig.
1); the precise location of capture of CAM5 is unknown. The
two other strains were both from sites (SL and BM) not
previously sampled. The new strain from SL was most closely
related to strains previously obtained from MT, a site 130 km to
the north of SL (Fig. 3c). The new strain from BM was most
closely related to the clade composed of strains from EK and
HIV-1 group N. Although we were not able to amplify pol
sequences from this BM1034 sample, we obtained a 500 bp
region from gag, which also clustered with the EK/HIV-1 group
N clade (data not shown). The BM and EK sites both lie in the
Table 2
Genetic identification of SIVcpz infected chimpanzees
Individual a Fecal
samples
Date of
sample
collection
Fecal
antibody
detection b
Fecal vRNA
detection c
MtDNA
haplotype
Locus d
D18S536
Locus d
D4S243
Locus d
D10S676
Locus d
D9S922
Locus d
D2S1326
Locus d
D2S1333
Locus d
D4S1627
Locus d
D9S905
pol gp41 V3
17 LB714 21/04/05 Pos + + + HT1 173/177 227/227 173/177 286/306 252/268 305/317 220/224 278/286
18 LB715 21/04/05 Pos + + + HT2 173/173 204/227 169/169 – / – 244/268 305/317 220/224 282/286
19 LB730 26/04/05 Pos − + − HT3 157/177 227/231 169/185 – / – 228/232 309/321 224/232 282/286
20 MB749 20/04/05 Pos − + − HT4 153/169 196/227 181/189 – / – 256/264 313/321 228/228 290/294
21 MB750 20/04/05 Pos + + − HT5 165/169 200/227 177/177 – / – 244/252 321/321 228/236 270/286
MB751 20/04/05 Pos + + − HT5 165/169 200/227 177/177 – / – 244/252 321/321 228/236 270/286
MB752 20/04/05 Pos − + − HT5 165/169 200/227 177/177 – / – 244/252 321/321 228/236 270/286
MB755 20/04/05 Pos − + − ND 165/169 200/227 177/177 – / – 244/252 321/321 228/236 270/286
MB758 20/04/05 Pos − − − ND 165/169 200/227 177/177 – / – 244/252 321/321 228/236 270/286
22 MB771 23/04/05 Pos − + − HT6 145/153 204/247 177/189 306/310 252/268 325/329 232/236 274/286
23 MB773 23/04/05 Pos − − − HT7 153/153 227/227 177/181 – / – 252/268 305/325 216/232 282/298
24 MB801 28/04/05 Pos + + + HT8 141/153 227/231 177/185 – / – 232/252 321/325 224/228 282/282
25 e MB774 23/04/05 Pos − − − HT9 157/169 227/227 177/177 – / – 232/256 317/325 212/236 282/286
MB775 23/04/05 Pos − − − HT9 157/169 227/227 177/177 – / – 232/256 317/325 212/236 282/286
MB784 24/04/05 Pos − − − HT9 157/169 227/227 177/177 – / – 232/256 317/325 212/236 282/286
MB785 24/04/05 Pos − − − HT9 157/169 227/227 177/177 – / – 232/256 317/325 212/236 282/286
MB788 28/04/05 Pos + − + HT9 157/169 227/227 177/177 – / – 232/256 317/325 212/236 282/286
MB791 28/04/05 Pos − − − HT9 157/169 227/227 177/177 – / – 232/256 317/325 212/236 282/286
MB802 28/04/05 Pos − + + HT9 157/169 227/227 177/177 – / – 232/256 317/325 212/236 282/286
26 MB776 23/04/05 Pos − − + HT10 165/173 227/231 177/185 – / – 244/268 317/325 232/236 282/286
27 MB790 28/04/05 Pos + − − HT11 149/153 247/247 185/189 294/302 240/248 297/313 224/228 282/298
28 MB803 28/04/05 Pos + + + HT12 161/173 227/227 177/177 – / – 232/256 329/333 228/232 282/282
29 MB897 26/04/05 Pos + + + HT13 165/173 196/223 185/185 – / – 228/232 321/329 228/236 282/286
30 DP931 06/02/05 Pos − − − HT14 141/157 227/235 181/185 294/298 252/256 313/313 224/232 282/282
DP942 06/02/05 Pos − + − HT14 141/157 227/235 181/185 294/298 252/256 313/313 224/232 282/282
DP949 08/02/05 Pos − + − HT14 141/157 227/235 181/185 294/298 252/256 313/313 224/232 282/282
31 DP933 06/02/05 Pos − + − HT15 153/169 204/231 181/185 276/298 238/252 313/329 228/232 290/290
DP935 06/02/05 Pos + − + HT15 153/169 204/231 181/185 276/298 238/252 313/329 228/232 290/290
DP937 06/02/05 Pos − − − HT15 153/169 204/231 181/185 276/298 238/252 313/329 228/232 290/290
DP943 06/02/05 Pos + + − HT15 153/169 204/231 181/185 276/298 238/252 313/329 228/232 290/290
DP948 06/02/05 Pos − − − HT15 153/169 204/231 181/185 276/298 238/252 313/329 228/232 290/290
32 SL969 27/06/05 Pos − − − HT16 169/173 204/235 177/185 286/290 252/264 305/321 228/232 286/286
SL993 28/06/05 Pos − − − HT16 169/173 204/235 177/185 286/290 252/264 305/321 228/232 286/286
SL994 28/06/05 Pos − − − HT16 169/173 204/235 177/185 286/290 252/264 305/321 228/232 286/286
SL995 28/06/05 Pos − + + HT16 169/173 204/235 177/185 286/290 252/264 305/321 228/232 286/286
SL996 28/06/05 Pos − − − HT16 169/173 204/235 177/185 286/290 252/264 305/321 228/232 286/286
33 BM1034 21/06/05 Pos − + + HT17 137/161 248/231 177/181 – / – 240/244 313/321 224/224 286/290
BM1040 21/06/05 Pos − + − HT17 137/161 248/231 177/181 – / – 240/244 313/321 224/224 286/290
Mix30/31 DP934 06/02/05 Pos − + + HT10 Mix Mix 181/185 Mix Mix 313/329 Mix 282/290
DP946 06/02/05 Pos + − − ND Mix Mix 181/185 Mix mix 313/329 Mix 282/290
ND: not done.
a Individuals are numbered in accordance to the previous survey (Keele et al., 2006) where 16 SIVcpzPtt-positive apes were identified.
b Antibody profiles are shown in Fig. 2.
c Pol fragments of samples MB751, MB790 and DP935 are ∼340 bp; the pol fragment of MB750 is 879 bp long; all other pol sequences are 888 bp in length.
d 8 STR loci were amplified from fecal DNA; 2 alleles per locus are shown; dashes indicate failure to amplify due to partial sample degradation; homozygous loci
were amplified at least seven times to exclude allelic dropout.
e Note that the microsatellite profile of ID25 is identical to that of ID11 reported previously, thus indicating the resampling of the same individual.
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apart (Fig. 3c).
With the addition of the new strains reported here, a new
aspect of the phylogeographic diversity of SIVcpzPtt is
emerging. The MB and LB strains are all derived from a
relatively small area spanning only about 100 km. For the
partial Gp41 sequence, the average amino acid diversity among
these strains is 15%, with a maximum pairwise difference of
26%. Although the DP strains do not form a monophyletic
clade, their diversity is not very different from that of the MB/
LB clade (average 16%, maximum 22%). Indeed, the gp41clade composed of strains from DP, BM and EK, as well as
previously characterized strains from captive chimpanzees from
Cameroon (CAM3, CAM5, CAM13), Gabon (GAB1, GAB2)
and an unknown origin (US), exhibits a similar level of diversity
(average 18%, maximum 25%), although these strains were
collected from a much wider geographic range. Thus, while
there are, as expected, numerous examples of closely related
strains at the same location reflecting local transmission, the
results from the DP site indicate that divergent lineages may
also be found at one location. The two lineages found at the DP
site represent the diversity seen across a much wider area
160 F. Van Heuverswyn et al. / Virology 368 (2007) 155–171including much of south central Cameroon, and even Gabon. In
contrast, the strains present in southeastern Cameroon (the MB
and LB sites) represent a much more isolated clade. Taken
together, the new strains of SIVcpzPtt reported here reinforce
our earlier interpretation of the origins of HIV-1 groups M and
N. In the gp41 tree, HIV-1 group M lies within the radiation of
MB/LB strains and the phylogenetic separation of this clade
from strains from other areas of west central Africa indicates
that group M most likely originated in southeastern Cameroon.
While HIV-1 group N lies within a larger clade of strains fromFig. 3. Phylogenetic analysis of partial Pol (polymerase) (a) and Env (gp41, envelope
(asterisks). Newly and previously identified SIVcpzPtt strains (Keele et al., 2006) ar
group M (U455, LAI), N (YBF30, YBF106) and O (Ant70, MVP5180) sequences
outgroup. Trees were inferred by the Bayesian method; numbers on nodes are percen
represent substitutions per site. Sites where positive samples were identified, as we
available are shown (c). Locations where SIVcpzPtt infection was found are color-c
from the previous survey are indicated in italics, while strains from the expanded suwidespread geographic origins, SIVcpzPtt strains closely
related to group N have only been found within the bend of
the Dja River in south central Cameroon, pointing to that area as
the likely source of that HIV-1 group.
Sequence analysis of two full-length SIVcpzPtt strains
To explore further the phylogeny of the SIVcpzPtt lineage, we
amplified two additional full-length SIVcpzPtt strains from fecal
samples collected at the MB (MB897) and DP (DP943) fieldtransmembrane protein) (b) sequences of the newly identified SIVcpzPtt strains
e highlighted by colors reflecting their collection sites (c). Representative HIV-1
are included, as well as SIVcpzPts sequences (ANT, TAN1-3) which form the
tage posterior probabilities (only values above 95% are shown). The scale bars
ll as the exact location of these positive samples when GPS coordinates were
oded to correspond with distinct SIVcpzPtt lineages shown in (a and b). Strains
rvey are highlighted in bold letters.
Fig. 3 (continued).
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gies (Santiago et al., 2003a,b; Keele et al., 2006; Takehisa et al.,
2007), complete MB897 and DP943 genomes were amplified as
sets of 11 and 14 partially overlapping subgenomic fragments,
respectively (Fig. 4). Direct sequence analysis of these RT–PCR
products yielded positions of base mixtures as well as nucleotide
differences in adjoining fragments in regions of sequence
overlap but none introduced nonsense or frameshift mutations
(Table 3). Both MB897 and DP943 consensus sequences
contained uninterrupted reading frames for all structural and
regulatory proteins as well as intact regulatory elements.
Previous analyses showed that the phylogenetic relationships
among SIVcpzPtt strains vary in different regions of the
genome (Keele et al., 2006), presumably reflecting recombina-
tion events during the divergence of the SIVcpzPtt clade.
Therefore we performed phylogenetic analyses on four regions
of the proteome, namely Gag, the first part of Pol (sites 1–700),
the remainder of Pol concatenated with Vif, and Env (Fig. 5c).
Consistent with the analyses based on partial Pol and Env
sequences, in all four trees MB897 formed a clade with the two
other strains from the same geographic region (MB66 and LB7)
and with HIV-1 group M, while DP943 formed a clade with
three strains whose precise geographic origins are unknown
(CAM3, CAM5 and US). However, within both clades, there
were significant differences in branching order among the fourtrees. For example, MP987 clustered with MB66 in two trees
(Pol1 and Env) but with LB7 in a third (Pol2), in each case with
high probabilities. Similarly, DP943 clustered with CAM3 in
two trees (Gag and Pol1), but outside a clade composed of
CAM3 and CAM5 in the other two trees; these results were
supported by high probability values in three of the four trees.
These well-supported differences in branching order are
evidence of comparatively recent recombination events during
the divergence of viruses within these clades, and thus imply
instances of dual infection.
There were also differences in branching order at deeper
points within the SIVcpzPtt clade (Fig. 5). For example, the
clade including EK505 and HIV-1 group N grouped with the
MB/LB/HIV-1 cluster in Gag and Pol1, but with another cluster
(DP943/CAM3/CAM5/US) in Pol2 and Env, while the relative
positions of MT145, GAB2 and the cluster of GAB1/CAM13
moved among all four trees. These results point to a number of
recombination events during the earlier divergence of SIVcpzPtt
strains.
Genetic diversity among gp120 V3-loop sequences from
different SIVcpz lineages
The V3 loop of the HIV-1 gp120 glycoprotein plays an
important role in coreceptor binding of the virus, determining
Fig. 4. Amplification of full-length SIVcpzPtt (MB897 and DP943) genomes from fecal virion RNA. The complete MB897 and DP943 genomes were amplified as
partially overlapping RT–PCR fragments (shaded boxes) from fecal virion RNA and sequenced without interim cloning (fragments are drawn to scale). Nucleotide
sequences are numbered from the beginning of the R region in the 5′ LTR.
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peptides derived from consensus V3-loop sequences of HIV-1
M, N and O can be used in ELISA assays to discriminate the
different HIV-1 group infections (Ayouba et al., 2000, 2001;
Mauclere et al., 1997; Simon et al., 2001; Vergne et al., 2003;
Yamaguchi et al., 2004, 2006). The V3 loop of HIV-1 typically
consists of 35 amino acids, but varies in length (range 31–39)
and exhibits extensive sequence diversity, presumably in
response to immune pressures. In contrast, V3 loop sequence
diversity has been found to be relatively low among previously
characterized SIVcpz sequences (Vanden Haesevelde et al.,
1996; Hahn et al., 2000; Bibollet-Ruche et al., 2004b). In this
study, we amplified the V2–V5 region for 10 new SIVcpz
strains, extending the number of available SIVcpz V3 loop
sequences to 27, with 23 derived from SIVcpzPtt and 4 from
SIVcpzPts. Phenetic of these new sequences, as well as others
reported in the past (Bibollet-Ruche et al., 2004b), reveals more
diversity among SIVcpz V3 loop sequences than previously
found (Fig. 6). With the exception of SIVcpzPttGAB2, which
has an unusually divergent V3 loop, the SIVcpz sequences fall
into two distinct phenetic clusters, one exclusively composed of
SIVcpzPtt strains from LB and MB, and the other containing all
other SIVcpz strains, including SIVcpzPts as well as HIV-1
group N sequences. These SIVcpz V3 sequences differ
significantly from those of HIV-1 group M and O, and may
thus represent distinct V3 serotypes. Among the SIVcpzPtt
variants most closely related to HIV-1 group M, the crown of
the V3 loop is characterized by the GPGQ motif, which is the
same in the human viruses. Interestingly, the second Gly foundin the GPG motif of one of these SIVcpz strains (MB66) was
replaced by a Ser; the biological significance of this change is
unclear. Most other SIVcpz strains, including those from P. t.
schweinfurthii, encode GPGM at the crown, while the HIV-1
group N strains and two SIVcpzPtt strains (MT145 and DP935)
encode GPAM.
Discussion
Our previous molecular epidemiological studies of wild-
living apes in Cameroon allowed us to trace the origin of HIV-1
groups M and N to geographically isolated chimpanzee
populations in southern Cameroon (Keele et al., 2006). We
also identified for the first time SIV infection in wild gorillas
and showed that this new lineage clustered within the SIVcpz
radiation, as a sister clade to HIV-1 group O (Van Heuverswyn
et al., 2006). In order to corroborate and extend these findings
and to study in more detail the genetic diversity of SIVcpz, we
conducted a more extensive survey of wild chimpanzee
populations including previous and new field sites. The results
from this new study confirm a wide but uneven distribution, as
well as significant phylogeographic clustering, of SIVcpzPtt.
We confirmed the high prevalence (30%) of SIVcpz infection in
southeastern Cameroon and the absence or low to moderate
prevalence (4% to 11%) in chimpanzee communities from the
south-central area. Finally, there is no evidence for SIVcpz
infection in P. t. vellerosus.
Thus, a total of 824 chimpanzee samples have now been
studied from wild chimpanzees in Cameroon, 746 from P. t.
Table 3
Positions of sequence ambiguities in MB897 and DP943 fecal population sequences
Virus Amplicon a Sequence ambiguity b Position in genome Protein c Codon Encoded amino acid
SIVcpzMB897 ⁎C A/G 1766 p6 Gag 32 K/E
⁎C A/G 1766 TF 47 E/G
⁎C A/G 1783 p6 Gag 37 E
⁎C A/G 1783 TF 53 T/A
⁎C–D G/A–G 2076 PR 86 G
⁎E A/C 2859 RT 248 E/D
⁎E A/G 2995 RT 294 T/A
H–I C–T 6213 Env 140 P–S
I–J A–G 7116 Env 441 K–D
I–J A–T 7118 Env 441 K–D
I–J G–C 7124 Env 443 E–D
I–J A–C 7154 Env 453 E–D
⁎K C/T 8108 Env 771 L
⁎K C/T 8108 Rev 97 R/C
⁎K C/T 8246 Env 817 I
SIVcpzDP943 ⁎B A/G 687 p17 Gag 110 R
⁎B C/T 1312 p24 Gag 190 L
D–E C–T 2711 RT 192 D
E–F A–G 3419 RT 428 Q
⁎I C/G 6343 Env 174 Q,H,P/E,D,A
⁎I A/C 6344 Env 174 Q,H,E,D/P,A
⁎I G/T 6345 Env 174 Q,E,P,A/H,D,P,A
⁎I A/C 6356 Env 178 N/T
⁎I G/T 6360 Env 179 K/N
⁎I A/G 6567 Env 248 Q
⁎I C/T 6605 Env 261 T/I
⁎I C/T 6608 Env 262 A/V
⁎I C/G 6619 Env 266 H/D
⁎I A/C 6626 Env 268 T/K
⁎I A/G 6628 Env 269 K/E
⁎I A/G 6637 Env 272 K/E
⁎I A/G 6787 Env 322 I/V
⁎I A/C 6816 Env 331 L/F
⁎I A/T 6819 Env 332 K/N
⁎I A/G 6826 Env 335 M/V
K–L A–G 7749 Env 642 Q
a The location of MB897 or DP943 amplicons is shown in Fig. 1.
b Dashes (–) indicate nucleotide differences between adjoining fragments in regions of sequence overlap; slashes (/) indicate positions of base mixtures; the latter are
also highlighted by asterisks on the corresponding amplicon.
c p6, p17 and p24 Gag, viral core proteins; TF, Transframe peptide resulting from processing of Pr160 Gag–Pol polyprotein precursor; PR, protease; RT, reverse
transcriptase; Env, envelope glycoprotein.
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new SIVcpzPtt strains. All of these newly identified SIVcpzPtt
strains were found to fall within the radiation of SIVcpz fromP. t.
troglodytes apes, confirming that chimpanzees from east and
west central Africa harbor subspecies-specific SIVcpz lineages.
Within Cameroon, chimpanzee populations that are sepa-
rated by major geographical barriers also harbor distinct
SIVcpzPtt lineages. All SIVcpzPtt strains from the MB and
LB sites formed a single well-supported clade that included
HIV-1 group M, and this clade was exclusively found in
southeastern Cameroon. Similarly, samples from the EK and
BM sites in the Dja Reserve, just south of the Dja River, were
much more closely related to HIV-1 group N than were any
other identified SIVcpz strains. While strains from neighbour-
ing chimpanzee communities collected over a small area often
clustered closely together in the phylogenies, it is also important
to note that certain communities harbor rather divergent
SIVcpzPtt lineages. The most striking examples were LB714/715 and LB730, which were collected at a distance of 1 km
from each other within the LB site, and DP25/DP206 and
DP942/943 from DP, which were collected at a single field site.
Moreover, the genetic diversity among SIVcpzPtt strains from a
relatively small region within the south east was comparable to
that observed among all other SIVcpzPtt strains, collected from
sites across south-central Cameroon (DP, SL and MT), as well
as from captive chimpanzees from the same area (CAM3,
CAM5 and CAM13) and from Gabon (GAB1 and GAB2)
(Corbet et al., 2000; Nerrienet et al., 2005; Peeters et al., 1989).
Our studies in Cameroon suggest that rivers may play a
major role in the phylogeographic clustering of SIVcpz. For
example, the SIVcpzPtt strains most closely related to HIV-1
group N are found only in the north of the Dja Reserve, whereas
just across the Dja River divergent lineages are found. Rivers
could also explain the absence of SIVcpz infection in some
areas. For example, the highest SIVcpzPtt prevalences were
observed at the MB and LB sites in south east Cameroon, while
Fig. 5. Evolutionary relationships of full-length SIVcpz genomes. Phylogenetic analyses were performed on four major regions of the proteome: Gag (upper left), Pol
sites 1–700 (Pol1, upper right), Pol sites 701–923 concatenated with Vif (Pol2, lower left), and Env (lower right). The new SIVcpzPtt sequences are indicated by
asterisk. Representative HIV-1 group M (U455, LAI), N (YBF30, YBF106) and O (Ant70, MVP5180) sequences are included, as well as SIVcpzPts sequences (ANT,
TAN1–3) which form the outgroup. Numbers on branches indicate estimated posterior probabilities (only values greater than 90% are shown). The scale bars represent
0.05 (or 0.1 for Env) amino acid replacements per site.
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separated from MB and LB by the Boumba River. Long
distances may also play a role, although some viral lineages
have clearly been able to spread over a wide range. Overall, and
not unexpectedly, the genetic diversity among SIVcpzPtt strains
is heavily influenced by the geographic origin of their hosts.
We recently identified SIV in gorillas in Cameroon (Van
Heuverswyn et al., 2006). These viruses (SIVgor) cluster within
the SIVcpzPtt lineage and are most closely related to HIV-1
group O. The phylogenetic position of SIVgor implies that P. t.
troglodytes chimpanzees were the source of SIVgor. While we
have now screened a substantial number of new samples from
chimpanzees in Cameroon, including some from sites in areas
which overlap with the range of the SIV-positive gorillas, we
have not identified an SIVcpzPtt strain which is closely related
to SIVgor or HIV-1 group O. It is possible that, subsequent totransmission to gorillas, this lineage of SIVcpzPtt has become
extinct or had its origin outside Cameroon.
Two full-length genome sequences were characterized to
verify the phylogenetic relationships among the different
SIVcpzPtt lineages. Analysis of these sequences confirmed
previously reported ancient recombination events, for example
involving the ancestors of the EK strains (and hence HIV-1
group N), as well as the GAB2, MT145 and GAB1/CAM13
strains (Keele et al., 2006; Sharp et al., 2005). These analyses
also revealed evidence for more recent recombination events
among the strains in southeastern Cameroon (at MB and LB).
Thus, co-infection of individual chimpanzees by (at least) two
strains of SIVcpz has occurred on multiple occasions.
Although highly endangered, gorillas and chimpanzees
continue to be hunted, especially in west central Africa, and
remain a potential source of human infection (Matthews and
Fig. 6. Comparison of V3 loop sequences from the newly isolated SIVcpz with those of previously characterized representatives of the HIV-1/SIVcpz lineage. Single-
letter abbreviations for amino acid residues are compared to HIV-1 M subtype A1 92UG037. Dots indicate amino acid identity and dashes indicate gaps introduced for
better alignment. The phenetic similarities are indicated on the left.
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are now known to have crossed the species barrier to humans on
at least three occasions (Hahn et al., 2000; Sharp et al., 2005). In
addition, in West Africa there have been at least 8 cross-species
transmissions of SIV from sooty mangabeys leading to distinct
groups of HIV-2 (Damond et al., 2004; Santiago et al., 2005).
Thus it would be not surprising if additional cases of SIVcpz or
SIVgor cross-species transmissions had occurred, especially in
geographic regions where these viruses are most prevalent and
where hunting pressure is high. Since SIVcpz/SIVgor infections
are unlikely to be differentiated by commercial HIV-1 antibody
screening assays, such transmissions may have gone unrecog-
nized. As shown in our serological testing, some SIVcpzPtt
variants elicit antibody responses that are indistinguishable from
those observed in HIV-1 group M infections (see Western blot
profiles of SIVcpz infections from the MB and LB sites in Fig.
2), or from the HIV indeterminate Western blot profiles which
are often observed for HIV-1 group O infections (Gurtler et al.,
1994; De Leys et al., 1990; Loussert-Ajaka et al., 1994). It is thus
likely that some HIV-1 seropositive and/or seroindeterminant
individuals in west central Africa are infected with the
descendants of still other SIVcpz and/or SIVgor strains.
Although only a fraction of human antibody-positive samplesfrom west central Africa have been molecularly characterized,
such studies have already allowed the identification and
characterization of HIV-1 groups O and N in Cameroon (Gurtler
et al., 1994; De Leys et al., 1990; Simon et al., 1998). V3 peptide
ELISAs have been shown to reliably identify the majority of
HIV-1 groupM, N andO as well as dualM/O infections (Ayouba
et al., 2000, 2001; Mauclere et al., 1997; Simon et al., 2001;
Vergne et al., 2003; Yamaguchi et al., 2004, 2006). However,
10% of HIV-1-positive sera are untypeable (Vergne et al., 2003);
while this is most probably related to the high specificity and the
insufficient sensitivity of the assays, some of these samples may
represent infections with other HIV-1 variants resulting from
additional SIVcpz or SIVgor cross-species transmissions. It
should be emphasized that HIV-1 group N was initially
identified because the serum was non-reactive with HIV-1 M
and O peptides, but recognized a peptide derived from SIVcpz
(Simon et al., 1998). Subsequent genetic characterization of
HIV-1 group N confirmed its close genetic relationship with
SIVcpzPtt in the envelope gene (Corbet et al., 2000; Roques et
al., 2004; Simon et al., 1998).We identified a substantial number
of new SIVcpzPtt V3 loop sequences, which fall into distinct
phenetic clusters and differ from those of HIV-1 groupsM and O
by 44% to 69%, and likely represent distinct V3 serotypes. This
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of these SIVcpzPtt lineages and identify possible new SIVcpz or
SIVgor cross-species transmissions. If additional transmissions
have indeed occurred, it will be important to study to what extent
these new zoonoses have spread within the human population.
Such events would have important public health implications
and consequences for future AIDS treatment and vaccine
development. In addition to virus, host and socio-demographic
factors, high HIV-1 prevalences in certain rural areas, for
example around logging concessions, could also play a role in
the further spread of new transmissions, in particular by
recombination between HIV-1 and SIVcpz or SIVgor (Laurent
et al., 2004).
We have already sequenced full-length genomes for a subset
of the new SIVcpzPtt lineages. As a next step, it will be
important to characterize these viruses on a biological level to
elucidate the determinants of cross-species transmission and
host adaptation. These analyses may also identify factors related
to further spread of the virus; for example, it is currently
unknown whether the global spread of HIV-1 group M,
compared to the limited spread of HIV-1 groups N and O,
reflects characteristics of the progenitors of these viral clades or
simply different epidemiological opportunites that they encoun-
tered. While it seems that viral isolation from fecal material is
not possible, we have recently demonstrated that infectious
molecular clones of SIVcpz can be generated from fecal viral
consensus sequences from wild-living chimpanzees (Takehisa
et al., 2007). This new technology will allow the study of the
biological characteristics of the new SIVcpzPtt strains, and
yield better insights into their pathogenic potential.
In summary, the new SIVcpzPtt strains reported in this study
have corroborated and extended our previous findings regarding
the origins of HIV-1 groups M and N in southeastern and south
central Cameroon, respectively. We have observed a high
genetic diversity, generated by both divergence and recombina-
tion, among SIVcpzPtt strains from neighbouring chimpanzees
communities, and confirmed the phylogeographic clustering of
these viruses. Humans continue to have contact with the apes
harboring these viruses, and the possibility of additional SIVcpz
and/or SIVgor transmissions thus has to be considered.
Materials and methods
Sample collection and study sites
Fecal samples (n=725) were collected from wild-living
(non-habituated) apes at 15 forest sites, mainly located in the
southern part of Cameroon (Fig. 1). Twelve field sites were in
the range of the P. t. troglodytes subspecies and three were north
of the Sanaga River (TK, MF, and MP) in the P. t. vellerosus
range (Table 1). Seven of the fifteen sites (EK, BM, CP, TK,
BB, NK, and LB) were located in National Parks or Forest
Reserves, while the remainder were in non-protected areas with
considerable hunting pressure. In addition to the 7 previously
sampled sites (CP, DP, BQ, EK, MB, BB, and LB) (Keele et al.,
2006), 8 new field sites are included in this study: TK, MF, MP,
MG, KG, SL, BM, and NK. Samples were collected byexperienced trackers, preserved in RNAlater (a commercial
preservative of nucleic acids) (Ambion, Austin, TX), stored at
the base camps at room temperature (maximum 20 days), and
subsequently transported to a central laboratory in Yaounde.
Collection site, date, global positioning system (GPS) coordi-
nates (when available) and species origin, as identified by visual
inspection were recorded in the field.
Species and subspecies determinations
The species origin of the fecal samples was determined by
mitochondrial DNA (mtDNA) analysis as described previously
(Keele et al., 2006; Van Heuverswyn et al., 2006). Fecal DNA
was extracted using the QIAamp Stool DNA Mini kit (Qiagen,
Valencia, CA). Briefly, 1.5 ml of fecal RNAlater mixture was
resuspended in stool lysis buffer and clarified by centrifugation.
The supernatants were treated with an InhibitEx tablet (Qiagen,
Valencia, CA), subjected to proteinase K digestion, and passed
through a DNA binding column. Bound DNAwas eluted in 50–
150 μl elution buffer, and 5 μl (aliquots) were used for mito-
chondrial DNA amplification. First, a ∼450- to 500-bp mtDNA
fragment spanning the hypervariable D loop was amplified from
fecal DNA using primers L15997 (5′-CACCATTAGCACC-
CAAAGCT-3′) and H16498 (5′-CCTGAAGTAGGAACCA-
GATG-3′). Phylogenetic analysis of these D loop sequences
allowed identification of all chimpanzee samples and their
subspecies classification (P. t. troglodytes or P. t. vellerosus).
Whereas the majority of gorilla samples could also be identified
with this approach, some samples yielded amplification products
of poor quality and were reanalyzed by amplifying a 386-bp
mtDNA fragment spanning the 12SrRNA gene (using primers
12S-L1091 5′-AAAAAGCTTCAAACTGGGATTAGATACC-
CCACTAT-3′ and 12S-H1478 5′-TGACTGCAGAGGGTGAC-
GGGCGGTGTGT-3′). Sequence analysis of these fragments
revealed that most of them were gorillas, but that some samples
were not from apes and belonged to other non-human primates
such as baboons or agile monkeys. Samples that scored negative
in both amplification assays were considered as representing
degraded material.
Microsatellite analyses
Fecal DNAwas extracted from all SIVcpz antibody-positive
samples for microsatellite analysis to determine the number of
infected individuals as previously described (Keele et al., 2006).
All samples were genotyped at 7 loci (D18s536, D4s243,
D10s676, D2S1326, D2S1333, D4S1627 and D9S905)), with
an additional locus (D9s922) amplified for a select number of
samples. All PCR reactions were performed in duplicate.
Individuals whose genotype appeared homozygous were
amplified a minimum of seven times to exclude allelic drop out.
Detection of SIVcpz antibodies in RNAlater preserved fecal
chimpanzee samples
All chimpanzee fecal samples were tested for the presence of
HIV-1 cross-reactive antibodies, using the INNO-LIA HIV I/II
167F. Van Heuverswyn et al. / Virology 368 (2007) 155–171Score Confirmation test (Innogenetics, Ghent, Belgium) as
previously described (Van Heuverswyn et al., 2006). This test
configuration includes HIV-1 and HIV-2 recombinant proteins
and synthetic peptides, coated as discrete lines on a nylon strip.
INNO-LIA-positive samples were also tested by Western blot
analysis as reported previously (Calypte Biomedical; Rockville,
MD) (Keele et al., 2006). RNAlater precipitated immunoglo-
bulin is resolubilized by diluting fecal/RNAlater mixtures
(1.5 ml) with PBS–Tween 20 (7.5 ml), followed by inactivation
of the mixture for 1 h at 60 °C, centrifugation (3500×g for
10 min) to clarify the solution, and then dialyzing it against PBS
overnight at 4 °C. The reconstituted extracts were then
subjected to immunoblot analysis. Importantly, all samples
containing SIVcpz antibodies scored positive in both assays.
Amplification of SIVcpz sequences from fecal RNA
Fecal RNA was extracted from all samples with HIV cross-
reactive antibodies and subjected to RT-PCR amplification using
SIVcpz/HIV-1 consensus primers in env (gp41 ectodomain)
(∼390 bp) and pol (∼340 bp or∼890 bp) regions as previously
described (Keele et al., 2006; Van Heuverswyn et al., 2006). To
amplify the V3 region, additional primer sets were designed,Table 4
Primer sets used to amplify partial SIVcpz pol and env (gp41 and V3) sequences
Gene Round of
nested PCR
Primer Size (b)
pol 1 CPZ-pol-F1 823
CPZ-pol-R1
pol 2 CPZ-pol-F2 340
CPZ-pol-R2
pol 1 CPZ-pol-F1a 1207
CPZ-pol-R1
or
CPZ-pol-F1b
CPZ-pol-F1c 1228
CPZ-pol-R1b
pol 2 CPZ-pol-F2a 941
CPZ-pol-R2
or
CPZ-pol-F2b 1034
env (gp41) 1 CPZ-gp41-F1 591
CPZ-gp41-R1
env (gp41) 2 CPZ-gp41-F2 467
CPZ-gp41-R2a
Or
CPZ-gp41-R2b 450
env (V3) 1 M-V3-CPZ-F1 631
M-V3-CPZ-R1
env (V3) 2 M-V3-CPZ-F2 603
M-V3-CPZ-R2
env (V3) 1 N-V3-CPZ-F1 793
N-V3-CPZ-R1
env (V3) 2 N-V3-CPZ-F2 511
N-V3-CPZ-R2
env (V3) 1 DP-V3-CPZ-F1 970
DP-V3-CPZ-R1
env (V3) 2 DP-V3-CPZ-F2 919
DP-V3-CPZ-R2
a Y=C/T, W=A/T, R=A/G, H=A/C/T, B=C/G/T, S=G/C, K=G/T, D=A/G/T, N
b a: Courgnaud et al., 2001; b: Santiago et al., 2003b; c : Van Heuverswyn et al.,based on the phylogenetic clustering of the SIVcpz strains (all
primers are listed in Table 4). cDNAwas synthesized using the
R1 primer, followed by nested PCR using primers F1/R1 and F2/
R2. For one sample a small fragment (∼520 bp) in gag was
amplified with the following primer set: CPZ-GAGF1 (5′-
ATGGGWGCGAGRGCGTC-3′), CPZ-GAGR1 (5′-GCTT-
CWGCTARNACYCTWGCCTTATG-3′), CPZ-GAGF2 (5′-
ATGAAACATHTAGTWTGGGCMAG-3′) and CPZ-GAGR2
(5′-TCCCAHTCNGCDGCTTCYTCATTGAT-3′). All RT-
PCR reactions were performed with the Expand Reverse
Transcriptase and the Expand Long Template PCR system
(Roche Diagnostics, Indianapolis, IN) according to the manu-
facturer’s instructions. Briefly, 10 μl of fecal vRNAwas used for
cDNA synthesis and 20 U of RNase Inhibitor (Ambion, Austin,
TX) was added to the RT–PCR mixture. The mixture was then
incubated for 1 h at 42 °C, followed by 5 min at 95 °C to
inactivate the enzyme. 10 μl of genomic DNAwas used for first-
round PCR amplifications and 5 μl of the first-round reaction
was used for the nested PCR with second-round primers, F2/R2,
by using the same thermocycling conditions. Mostly, PCR
amplifications included 35 cycles of denaturation (94 °C, 20 s),
annealing (50 °C, 30 s) and elongation (68 °C, 1 min) in a Peltier
Thermal Cycler (PTC-200). For some amplifications PCRSequence a Reference b
CCAGCNCACAAAGGNATAGGAGG a,b,c
ACBACYGCNCCTTCHCCTTTC a,b,c,d
GGAAGTGGATACTTAGAAGCAGAAGT b,c
CCAATYCCYCCYYTTYKYTTAAAATT c
ACCTGGATNCCWGANTGGGA c,d
ACBACYGCNCCTTCHCCTTTC a,b,c,d
GTTACCTGGGTACCTGAGTGGGA d
TGGTGGDCWGANTAYTGGCA d
ACTGCHCCYTCWCCTTTCCACAG d
TWYTATGTWGATGGRGCAGC c,d
CCAATYCCYCCYYTTYKYTTAAAATT c
ACCTGGATHCCHGANTGGGA d
TCTTAGGAGCAGCAGGAAGCACTATGGG d,e
AACGACAAAGGTGAGTATCCCTGCCTAA d,e
ACAATTATTGTCTGGTATAGTGCAACAGCA d,e
TTAAACCTATCAAGCCTCCTACTATCATTA d,
TCCTACTATCATTATGAATATTTTTATATA d,e
TTGAACCAATTCCYATWYAYTATTGTGC
ATTSCTYTYCCTACYCTYTGCCA
TATTGTGCHCCAGCTGGWTTTGC
TTACAATTTGTCTTATTCTGCAHGG
TTCCAATAYATTAYTGTGCACCACCAGG
CCTGGTGCTACTCCTATGGGTTCTAT
CAATGYACMCATGGAATAAAVCCAGT
GCATAAATTCCTTTTCCTACYCTTGTCCA
TCCTTTGAGCCAATTCCAATACA
CTGCGCCCATAGTGCTTCCTGCTGC
CCAATTCCAATACAYTAYTGTGCA
AACAGYGCHCCTAGTCCAAAGGCT
=A/C/T/G.
2006; d: Keele et al., 2006; e: Yang et al., 2000.
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b50 °C and/or touch-down PCR strategy). Extension times
varied depending on the size of the expected fragment and
were typically set at 1 min/kb. The resulting amplification
products were gel purified (Qiagen, Valencia, CA) and directly
sequenced using an automated sequencer (3130xl Genetic
Analyser, Applied Biosystems, Foster City, CA). The partial
pol, gp41 and V3-loop sequences of the new SIVcpzPttTable 5
Oligonucleotide primers used to amplify full-length MB897 and DP943 viral seque
Fragment a Forward primer b
MB897
A CON-A-F1 ACTGGGTCTCTCTKGTTAGACC M
CON-A-F2 GTCTCTCTKGTTAGACCAGATT M
Bd CON-B-F1 ATGGGTGCGAGAGCGTC C
CON-B-F2 ATGAAACATTTAGTATGGGCAAG C
Cd CON-C-F1 GAWGTRAARAMYTGGATGAC C
CON-C-F2 CARAATGCNAAYCCAGA C
D MB897-D-F1 GGGAATTGGAGGTTTTATAAAAGTAAGAC M
MB897-D-F2 AAAGAGCAATAGGTACAGTATTAGTAGGGC M
E MB897-E-F1 TCCAGCTAGGAATACCACACCC M
MB897-E-F2 CCAGTACATGGATGATCTATATGTAGGATC M
Fd CPZ-pol-F1C e TGGTGGDCWGANTAYTGGCA C
CPZ-pol-F2b e ACCTGGATHCCHGANTGGGA C
G MB897-G-F1 GAATTTGGAATTCCCTACAATCC C
MB897-G-F2 CAATGAACAAAGAGTTAAAGAAAAT C
H CON-H-F1 GCTATMATAAGAATYCTGCAACAACT M
CON-H-F2 TGYCAWCATAGCAGAATAGGCAT M
I MB897-I-F1 GCATGGAACAATAACATGGTAGACCAAATG M
MB897-I-F2 GGGATCAAAGCCTAAAGCCATGTG M
J MB897-J-F1 GTGCAGAATAAGACAAATTGTAA M
CON-J-F2 TGGCAAAGAGTAGGGAAAGGAAT C
K MB897-K-F1 GAAAGAGATTGATAACTACACAGA C
MB897-K-F2 TGGTCAAGCCTGTGGAATTGGTT C
DP943
A DP943-A-F1 GGTCTCTCTTGCTAGACCAG C
DP943-A-F2 GACCAGATTAGAGCCCGGGA D
D DP943-D-F1 AGAAGCTCTGCTAGACACAGGAGC C
DP943-D-F2 GGCACAGTGTTGGTGGGACC C
E CON-E-F1 CAAGGATGGAAAGGGTCACCRGCAAT D
CON-E-F2 CCATTCAGAMARCAGCATCCAGA D
G CON-G-F1 AGTGCTGCAGTTAAGGCAGCCTGTTGGTGG C
CON-G-F2 ATGGCAGTATTCATTCACAATTTT C
H DP943-H-F1 GCCATCAGAAAAGCTGTTTTAGGG D
DP943-H-F2 GGGCACCAACAGGTAGGGTCCC C
I DP943-I-F1 GAGCAAGACAGGACGATAGTGGAA D
DP943-I-F2 TGATGGAGAGGATCAGAGGCAGC D
J DP943-J-F1 GCATATTGTAATGTCAGCGCCACAG D
DP943-J-F2 CACAGATCAACAAGGAGGAGACCCGG D
K CPZ-gp41-F1 e TCTTAGGAGCAGCAGGAAGCACTATGGG C
CPZ-gp41-F2 e ACAATTATTGTCTGGTATAGTGCAACAGCA C
L DP943-L-F1 CCTAGGTCTGTGGGGCTGCTCAGG D
DP943-L-F2 CCTAACATGGCAAGACTGGGAC D
M CON-M-F1 AAATGGCTGTGGTATATAAAAAT C
CON-M-F2 GCTTAAGAAAGGTTAGGCAGGG C
N DP943-N-F1 CAAACTCTAGCATGGCTAGAAG C
DP943-N-F2 GGCTTTCCAGTTAGACCACAAGTACC C
a See Fig. 4 for position of individual fragments in the MB897 and D943 genome
b CON primers were designed according to HIV-1/SIVcpz consensus sequences. M
second-round forward primer; R1, first-round reverse primer; R2, second-round reve
D=A/G/T, and N=A/C/T/G.
c Size of PCR amplicons.
d Fragments B, C and F of MB897 and DP943 were amplified using identical pri
e For primer designation, also see Table 4.strains are available at GenBank under accession numbers:
AM696210–AM696248.
Generation of full-length fecal SIVcpzPtt population sequences
SIVcpzPttMB897 and DP943 genomes were amplified from
SIVcpz antibody-positive fecal samples collected at the MB
(sampled 26/04/2005) and DP (sampled 06/02/2005) field sites,nces
Reverse primer Amplicon c
B897-A-R1 CTTTTACTCTAATTCTTTGATG
B897-A-R2 TTCTGATCCTGTTGTGAGAGCTGG 553
ON-B-R1 TCYTTKCCACAATTRAARCA
ON-B-R2 GCTTCWGCTARNACYCTWGCCTTATG 985
ON-C-R1 ATYTTYCCTTCYTKYTCCAT
ON-C-R2 CTGGYTTYAATTTKACTGG 855
B897-D-R1 CAGATGACTATACTTTCCAGGGCTACT
B897-D-R2 TAACTCTAATTCTGCTTCCTGTGTGAG 998
B897-E-R1 TGAATGATCCCTAATGCATATTGTG
B897-E-R2 TCCCTCTATCAGTTACATATCCTGCTTT 843
PZ-pol-R1 e ACBACYGCNCCTTCHCCTTTC
PZ-pol-R2 e CCAATYCCYCCYYTTYKYTTAAAATT 1009
ON-G-R1 AGTTTTAGGCTGACTTCCTGGATG
ON-G-R2 TCTARRYTAGGATCTAYTGGCTCCAT 1169
B897-H-R1 TTTGGACAAGCCTGGGTTATGGCTG
B897-H-R2 CTTCTTATCTCTTAATTCTGT 919
B897-I-R1 TTCTGGCCTGTACCGTCAGCGT
B897-I-R2 GCGCCCATAGTGCTTCCTGCT 1193
B897-J-R1 AAGGGGTCTGGAACGACAAAGGTG
PZ-gp41-R2b e TCCTACTATCATTATGAATATTTTTATATA 789
ON-K-R1 AAGGCAAGCTTTATTGAGGC
ON-K-R2 CACTCAAGGCAAGCTTTAT 1428
ON-A-R1 CCTTCTGATCCTGTTKTGAGAGCTGG
P943-A-R2 GTTCTAACTGTTTTAATAGCTG 540
ON-D-R1 GRAGCTCATAGCCCATCCACAA
ON-D-R2 CAGGRGTAGTAAAMCCCCAAGT 733
P943-E-R1 CTCTGTTGGCTGCCCCATCTACA
P943-E-R2 CTGCCCCTGGTATGGGTTCTG 805
ON-G-R1 CCTGGRTGNWKCCAGGGCTC
ON-G-R2 CTTGTTCCATCTATCTTCT 808
P943-H-R1 ACACAGGCTTGTGAGGCCCAAAT
ON-H-R2 AGTGTTGTKTCTGCCTCTTTCCA 920
P943-I-R1 AATTCCCTTGCCCACTCTCATCCAGG
P943-I-R2 GAACAATGGGGTGGTGTTAC 1130
P943-J-R1 CCTGAGCAGCCCCACAGACCTAGG
P943-J-R2 CTGTTTAATGCCCCATACTGAGAGTTGC 643
PZ-gp41-R1 e AACGACAAAGGTGAGTATCCCTGCCTAA
PZ-gp41-R2b e TCCTACTATCATTATGAATATTTTTATATA 448
P943-L-R1 GGAGGTTCCGGAGATCGTCCC
P943-L-R2 GGATGTGCCTCTGCCTGGCTCTCCACC 361
ON-M-R1 TARCCCWTCCAGTCCYCCCTT
ON-M-R2 CCYCCCTTWYYTYTTAAAAA 771
ON-N-R1 CAAGGCAAGCTTTATTGAGGC
ON-N-R2 TTGAGGCTTAAGCAGTGGGTTC 637
s.
B897 and DP943 primers are strain specific. F1, first-round forward primer; F2,
rse primer. R=A/G, Y=C/T, M=A/C, K=G/T, W=A/T, H=A/C/T, B=C/G/T,
mer sets.
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2006; Takehisa et al., 2007). Briefly, cDNAwas synthesized by
adding fecal vRNA (10 μl) to a RT-PCR master mix containing
1× Buffer (Invitrogen; Carlsbad, CA), 0.5 mM dNTP, 5 mM
dithiothreitol, 2 pmol of primer, 20 U of RNase inhibitor
(Ambion, Austin, TX), and 200 U of SuperScript RT III
(Invitrogen), and by incubating the mixture for 3 h at 50 °C.
MB897 cDNA (6 μl) was added to a PCR mix consisting of 1×
Expand Buffer II (Roche Diagnostics; Indianapolis, IN),
0.5 mM dNTP, 500 nM of PCR primers, 25 μg of bovine
serum albumin and 3.75 U of Expand High-Fidelity polymerase
mixture (Roche Diagnostics). Amplification conditions for both
first-round and nested PCR included 35 cycles of denaturation
(94 °C, 0.5 min), annealing (53–60 °C, 0.5 min), and extension
(68 °C, 1 min). DP943 amplification was conducted similarly
except for using 10 μl cDNA, 0.4 mM dNTP, 400 nM primers
and amplification conditions that included 55 cycles of
denaturation (94 °C, 0.5 min), annealing (45–52 °C, 0.5 min)
and extension (68 °C, 1.5 min). The primers used are listed in
Table 5. Amplicons were gel-purified and sequenced directly
using an ABI 3730 DNA Analyzer using Sequencer version 4.6
(Gene Codes Corporation, Ann Arbor, MI). Chromatograms
were carefully examined for positions of base mixtures (Table
3). In addition, nucleotide differences between adjoining
fragments in regions of sequence overlap were recorded
(Table 3). The full-length MB897 (9167 bp) and DP943
(9247 bp) population sequences are available at GenBank under
the accession numbers EF535994 and EF535993, respectively.
Phylogenetic analyses of SIVcpz sequences
The new SIVcpzPtt nucleotide sequences were translated
and compared to various previously published sequences (see
below). Protein sequences were aligned using ClustalW
(Thompson et al., 1994); where necessary, minor manual
adjustments were performed in SeaView (Galtier et al., 1996)
and sites that could not be unambiguously aligned or contained
a gap in any sequence were excluded from the analyses.
Phylogenies were inferred by the Bayesian method (Yang and
Rannala, 1997), implemented in MrBayes version 3.1 (Ronquist
and Huelsenbeck, 2003), run for 1,000,000 generations.
Parameters were examined with the Tracer program (http://
evolve.zoo.ox.ac.uk/software.html/id%3Dtracer). For the ana-
lyses of partial Pol and gp41 sequences, the numbers of amino
acid sites examined were 296 and 126, respectively. Using the
mixed model in MrBayes indicated that the rtREV model of
amino acid change (Dimmic et al., 2002) was most appropriate;
this model was used with gamma-distributed rates across sites.
For the analyses of full-length sequences, four major regions of
the proteome were analyzed: Gag, Pol1, Pol2, and Env. The Pol
sequence was divided at the position of a recombination
breakpoint previously identified in HIV-1 group N (Gao et al.,
1999). In Pol2, the carboxy-terminal region of Pol was
concatenated with Vif; in the region of overlap between Pol
and Vif, only the Vif sequence was included. The JTT model of
amino acid change (Jones et al., 1992) was used, with gamma
distributed rates across sites. For the analysis of the V3-loopsequences, a phenetic dendrogramwas estimated by the UPGMA
method from a distance matrix of uncorrected sequence
differences usingNEIGHBOR from the PHYLIP package version
3.64 (Felsenstein, 2004).
GenBank accession numbers for full-length sequences used in
comparative analyses are as follows: HIV-1 group M subtype A
U455 (M62320) and subtype B HXB2 (K03455), HIV-1 group N
YBF30 (AJ006022) and YBF106 (AJ271370) HIV-1 group O:
ANT70 (L20587) and MVP5180 (L20571); SIVcpzPtt CAM3
(AF115393), CAM5 (AJ271369), CAM13 (AY169968), EK505
(DQ373065), GAB1 (X52154), GAB2 (AF382828), LB7
(DQ373064), MB66 (DQ373063), MT145 (DQ373066), US
(AF103818); SIVcpzPts: ANT (U42720), TAN1 (AF447763),
TAN2 (DQ374657), TAN3 (DQ374658). GenBank accession
numbers for additional partial pol and gp41 sequences used in
comparative analyses are as follows: SIVcpzPtt MT115
(DQ370395, DQ370370), DP206 (DQ370403, DQ370375),
DP25 (DQ370405, DQ370378), EK502 (DQ370408,
DQ370381), EK516 (DQ370382), EK519 (DQ370411,
DQ370383), MB23 (DQ370413, DQ370388), MB192
(DQ370415, DQ370392), MB317 (DQ370416, DQ370387),
MB245 (DQ370417, DQ370385), LB186 (DQ370418), MB248
(DQ370386); SIVgor: BQ664 (AM296488, AM296484), CP684
(AM296489, AM296485), CP1434 (AM296487), CP1436
(AM296491). GenBank accession numbers for additional V3
loop sequences used in comparative analyses are as follows:HIV-1
groupM:A1 92UG037 (U51190), A2 97CDKTB48 (AF286238),
B BK132 (AY173951), C ETH2220 (U46016), D 94UG114
(U88824), 01-AE CM240 (U54771), F1 VI850 (AF077336), F2
02CM_0016BBY (AY371158), G DRCBL (AF084936), H
VI991 (AF190127), K EQTB11C (AJ249235).
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